Associate Scientist, Platform Technology

At Editas Medicine, we are pioneering the possible. Our mission and commitment is to translate the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.

Why Choose Editas?

At Editas Medicine, we’re a team of courageous problem solvers, harnessing the power and potential of CRISPR gene editing to transform the future of medicine. Driven by a shared purpose to serve people living with serious diseases, we succeed together through collaboration, mutual respect, and innovation. If you want to be part of a team where your voice is heard and respected, where you can operate at the forefront of gene editing, and push the boundaries of what’s possible in medicine, come join us and become an Editor!

Decoding The Role:

As an Associate Scientist, Platform Technology, you’ll be a vital contributor to our mission and our success. In this role, you will use various CRISPR delivery systems to execute high-throughput screens, and extract samples for NGS (DNA), RT-ddPCR (RNA) and protein (flow or Western blots/Jess automated blots) readouts to identify lead guides across our internal and external programs. You will track screens through the LIMs and document in your ELN and be responsible for the analysis and summary of the screens to inform follow-up experiments. An ideal candidate should have a strong background in immortalized (hepatocytes) and primary cell culture (HSC, T cells) and have experience screening in these cell types using various CRISPR delivery systems, including RNPs and LNPs.

Characterizing Your Impact:

As the Associate Scientist, Platform Technology, you will:

• As the Associate Scientist I, Platform Technology, you will be responsible for:
• Lead guide design, screening and selection of lead guide using editing and/or function assays for internal and external partner programs.
• Analyze and summarize screening results into proper documentation (ELN, Study Reports) 
• Implementation of a high-through LNP screening workflow, including automated LNP-formulations 
• Assist with RNP complexation and perform QC for internal program use 

The Ideal Transcript:

To thrive in this role, you’ll need:

• B.S. in cell biology, or related field with 5+ years of relevant experience in industry; or M.S. in cell or molecular biology with 2+ years of relevant experience in industry 
• Independently design and run screening experiments, extract gDNA, submit for sequencing, analyze, and present data 
• Experience with mammalian cell culture, including immortalized and primary cells (ex. Liver Cells and HSCs) 
• Proficient in executing and analyzing functional assays including flow cytometry and western blots 
• Experience working with different screening modalities such as guide RNAs and LNPs and knowing how to formulate both RNP and LNPs 
• Experience with data analysis software such as PRISM, Tableau, and FlowJo
• Familiar in molecular biology analyses such as qPCR and ddPCR 
• Familiar working with lab automation including both liquid handling robots (Biomek I7s, Mantis, Echo) and plate readers (Envision) 
• Excellent communication and interpersonal skills fostering effective teamwork 

Benefits Summary:

Editas provides a comprehensive array of benefits to all employees, including a Blue Cross Blue Shield PPO Medical Plan, a company-funded Health Savings Account, Dental and Vision Insurance, Life and Disability Insurance, Dependent Care Account, Tuition Reimbursement, 401(k) plan with company match, Employee Stock Purchase Plan, Employee Assistance Plan, Wellness Programs, and a flexible Paid Time Off policy.

Aspire to be an Editor? We invite you to apply and join us at the forefront of innovation and be a key contributor to realizing Editas Medicine's mission of developing transformative medicines for people living with serious diseases..